Skip to content

Study · Animal study (in vivo) · mouse · 2010

5 results

Synergistic protective effects of humanin and necrostatin-1 on hypoxia and ischemia/reperfusion injury.

Xu X, Chua KW, Chua CC, Liu CF, Hamdy RC, Chua BH

Brain research1 Aug 2010Cited by 116 (Europe PMC)

PMID20682300 (opens in a new tab)PMCIDPMC3412340 (opens in a new tab)DOI10.1016/j.brainres.2010.07.080 (opens in a new tab)PepBankPUB-20682300
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with middle cerebral artery occlusion, HNG reduced cerebral infarct volume from 59.3 ± 2.6% to 47.0 ± 2.3%.

    In plain wordsIn mice with a blocked brain artery, the humanin analog HNG reduced the size of brain damage.

    Peptide
    Humanin
    Outcome
    DecreaseCerebral infarct volume
    Study

    mousen: not reported in source

    Middle cerebral artery occlusion 75 min then 24 h reperfusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with HNG or Nec-1 reduced cerebral infarct volume from 59.3 ± 2.6% to 47.0 ± 2.3% and 47.1 ± 1.5%, respectively.
    2 context sentences
    Summary · context
    Mice underwent middle cerebral artery occlusion for 75 min followed by 24h reperfusion.
    Summary · context
    Mice were administered HNG and/or Nec-1 (i.c.v.) at 4h after reperfusion.
  2. 02LabIn vitro (cells)Efficacy outcome

    In mouse primary cortical neurons after oxygen-glucose deprivation, HNG alone protected against cell death.

    In plain wordsIn cells, the humanin analog HNG alone protected mouse brain cells from damage caused by lack of oxygen and glucose.

    Peptide
    Humanin
    Outcome
    IncreaseCell viability after oxygen-glucose deprivation
    Study

    mousen: not reported in source

    Primary cortical neurons after oxygen-glucose deprivation
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Nec-1 or HNG alone had protective effects on OGD-induced cell death.
    2 context sentences
    Summary · context
    Cultured mouse primary cortical neurons were incubated with Nec-1, HNG or both in a hypoxia chamber for 60 min.
    Summary · context
    Cell viability was determined by MTS assay at 24h after oxygen-glucose deprivation (OGD) treatment.

Studies that did not test the peptide alone3

In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Humanin.

  1. 03AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In mice with middle cerebral artery occlusion, combined HNG and Nec-1 treatment improved neurological scores.

    In plain wordsIn mice with a blocked brain artery, HNG together with Nec-1 improved nerve function scores.

    Peptide
    Humanin
    Outcome
    IncreaseNeurological scores with combined HNG and Nec-1
    Study

    mousen: not reported in source

    Middle cerebral artery occlusion 75 min then 24 h reperfusion
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Combined treatment with HNG and Nec-1 improved neurological scores
    2 context sentences
    Summary · context
    Mice underwent middle cerebral artery occlusion for 75 min followed by 24h reperfusion.
    Summary · context
    Mice were administered HNG and/or Nec-1 (i.c.v.) at 4h after reperfusion.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  2. 04AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In mice with middle cerebral artery occlusion, combined HNG and Nec-1 treatment decreased infarct volume to 38.6 ± 1.5%.

    In plain wordsIn mice with a blocked brain artery, HNG together with Nec-1 reduced the size of brain damage.

    Peptide
    Humanin
    Outcome
    DecreaseCerebral infarct volume with combined HNG and Nec-1
    Study

    mousen: not reported in source

    Middle cerebral artery occlusion 75 min then 24 h reperfusion
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    and decreased infarct volume to 38.6 ± 1.5%.
    2 context sentences
    Summary · context
    Mice underwent middle cerebral artery occlusion for 75 min followed by 24h reperfusion.
    Summary · context
    Mice were administered HNG and/or Nec-1 (i.c.v.) at 4h after reperfusion.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  3. 05LabNot a test of Humanin aloneIn vitro (cells)Efficacy outcome

    In mouse primary cortical neurons after oxygen-glucose deprivation, combined HNG and Nec-1 gave more neuroprotection than Nec-1 alone or HNG alone.

    In plain wordsIn cells, HNG together with Nec-1 protected mouse brain cells more than either one alone.

    Peptide
    Humanin
    Outcome
    IncreaseCell viability with combined HNG and Nec-1
    Study

    mousen: not reported in source

    Primary cortical neurons after oxygen-glucose deprivation
    Comparator
    Nec-1 alone or HNG alone
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Combined treatment with Nec-1 and HNG resulted in more neuroprotection than Nec-1 or HNG alone.
    2 context sentences
    Summary · context
    Cultured mouse primary cortical neurons were incubated with Nec-1, HNG or both in a hypoxia chamber for 60 min.
    Summary · context
    Cell viability was determined by MTS assay at 24h after oxygen-glucose deprivation (OGD) treatment.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.